CSBR
- Champions Oncology, Inc.
()
Overview
Company Summary
Champions Oncology, Inc. (CSBR) is a company that is primarily focused on revolutionizing the way cancer patients are treated through the development and commercialization of personalized cancer care solutions. Their innovative approach involves using patient-derived xenograft (PDX) models to provide valuable insights into individual patient responses to different anticancer treatments.
Champions Oncology achieves this by harvesting live tumor tissue from patients and implanting it into immune-deficient mice, creating PDX models. These models serve as highly accurate replicas of the patient's tumor, preserving its genetic characteristics and behavior. By studying these models, the company can accurately predict and evaluate patient responses to a wide range of anticancer treatments, offering personalized therapeutic strategies and optimizing patient outcomes.
In addition to developing patient-derived models, Champions Oncology also offers a range of preclinical services to assist pharmaceutical and biotechnology companies in their drug development efforts. This includes testing the efficacy of new therapies on PDX models, determining potential adverse effects, and assessing drug sensitivity and resistance. By leveraging their comprehensive database of PDX models and associated patient data, the company can provide essential insights into treatment response rates and enable more efficient drug development processes.
Furthermore, Champions Oncology provides comprehensive clinical solutions to oncologists, assisting them in making informed decisions regarding patient treatment plans. By analyzing tumor samples and utilizing their extensive PDX database, the company helps doctors identify the most appropriate and effective treatment options for their patients. This personalized medicine approach aims to enhance patient care by tailoring therapies to the specific genetic and molecular characteristics of the tumor.
Overall, Champions Oncology plays a crucial role in advancing the field of personalized oncology, providing a bridge between preclinical research and clinical practice. By utilizing patient-derived models and their expansive data resources, the company seeks to improve cancer outcomes and accelerate the discovery and development of novel anticancer therapies.